Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Senate Skips Critical Measures In Step-By-Step 'Cures'

This article was originally published in Scrip

Executive Summary

While many stakeholders in the biomedical community were happy just to see the Senate Health, Education, Labor and Pensions (HELP) Committee finally unveil a plan for moving forward with legislation aimed at making changes at the FDA and the National Institutes of Health (NIH) intended to accelerate medical innovation, there also was disappointment that the step-by-step strategy proposed by Sen. Lamar Alexander (R-TN), the panel's chairman, ignores several measures, like one focused on antibiotics development, that were included in a mega-bill adopted by the House last July – the 21st Century Cures Act.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register